Dow Jones

39,512.84

0.32%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

ARTL

Artelo Biosciences (ARTL)

Artelo Biosciences Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ARTL

1 2 3 4 5 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
10/05/2024	08:00	GlobeNewswire Inc.	Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th	NASDAQ:ARTL	Artelo Biosciences Inc
23/04/2024	07:30	GlobeNewswire Inc.	Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	NASDAQ:ARTL	Artelo Biosciences Inc
22/04/2024	07:30	GlobeNewswire Inc.	Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time	NASDAQ:ARTL	Artelo Biosciences Inc
25/03/2024	07:00	GlobeNewswire Inc.	Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update	NASDAQ:ARTL	Artelo Biosciences Inc
12/03/2024	08:15	GlobeNewswire Inc.	Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge	NASDAQ:ARTL	Artelo Biosciences Inc
23/01/2024	07:30	GlobeNewswire Inc.	Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy	NASDAQ:ARTL	Artelo Biosciences Inc
08/01/2024	07:30	GlobeNewswire Inc.	Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12	NASDAQ:ARTL	Artelo Biosciences Inc
05/12/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany	NASDAQ:ARTL	Artelo Biosciences Inc
30/11/2023	08:00	GlobeNewswire Inc.	Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany	NASDAQ:ARTL	Artelo Biosciences Inc
13/11/2023	07:02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ARTL	Artelo Biosciences Inc
13/11/2023	07:00	GlobeNewswire Inc.	Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:ARTL	Artelo Biosciences Inc
09/11/2023	08:00	GlobeNewswire Inc.	Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers	NASDAQ:ARTL	Artelo Biosciences Inc
02/11/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023	NASDAQ:ARTL	Artelo Biosciences Inc
04/10/2023	07:30	GlobeNewswire Inc.	Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia	NASDAQ:ARTL	Artelo Biosciences Inc
13/09/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th	NASDAQ:ARTL	Artelo Biosciences Inc
07/09/2023	07:00	GlobeNewswire Inc.	Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12	NASDAQ:ARTL	Artelo Biosciences Inc
06/09/2023	08:00	GlobeNewswire Inc.	Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th	NASDAQ:ARTL	Artelo Biosciences Inc
05/09/2023	08:00	GlobeNewswire Inc.	Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th	NASDAQ:ARTL	Artelo Biosciences Inc
10/08/2023	07:00	GlobeNewswire Inc.	Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update	NASDAQ:ARTL	Artelo Biosciences Inc
08/08/2023	15:57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARTL	Artelo Biosciences Inc
08/08/2023	15:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARTL	Artelo Biosciences Inc
19/07/2023	08:00	GlobeNewswire Inc.	Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023	NASDAQ:ARTL	Artelo Biosciences Inc
16/07/2023	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ARTL	Artelo Biosciences Inc
10/07/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11	NASDAQ:ARTL	Artelo Biosciences Inc
07/07/2023	07:23	Edgar (US Regulatory)	Form DEL AM - Delaying amendment	NASDAQ:ARTL	Artelo Biosciences Inc
06/07/2023	15:31	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ARTL	Artelo Biosciences Inc
28/06/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium	NASDAQ:ARTL	Artelo Biosciences Inc
27/06/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium	NASDAQ:ARTL	Artelo Biosciences Inc
26/06/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium	NASDAQ:ARTL	Artelo Biosciences Inc
07/06/2023	07:30	GlobeNewswire Inc.	Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium	NASDAQ:ARTL	Artelo Biosciences Inc